Lynk Pharmaceuticals Co. Ltd., a China-based clinical stage company, announced on Wednesday that it dosed the first patient with LNK01001 in its Phase II clinical trial aimed at ankylosing spondylitis, a chronic inflammatory disorder of unknown origin that primarily affects the spine, sternum, and large joints in the body.
LNK01001 is a JAK1 selective inhibitor intended to treat autoimmune diseases.
This study is a randomised, double-blind, placebo-controlled Phase II study assessing the safety and efficiency of LNK01001 capsules in patients with active ankylosing spondylitis. LNK01001 completed phase one clinical studies in healthy subjects in China and in Australia in the summer of 2021, sponsored by Lynk Pharmaceuticals and its US partner, respectively, and Phase II clinical studies for rheumatoid arthritis are presently underway.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial